Zepbound in New York (2026)
tirzepatide · GLP-1 weight management · New York
About Zepbound
Dual GLP-1/GIP agonist for weight management. ~20% body weight loss in trials — strongest weight-loss drug currently available.
See the full Zepbound review for dosing, efficacy data, side effects, and the full pharmacy + telehealth program comparison.
Insurance coverage for Zepbound in New York
NY Medicaid (NYRx) excludes drugs used for weight loss under 18 NYCRR §505.3(g)(3). GLP-1s are covered only for Medicaid-covered indications such as type 2 diabetes.
| Carrier | Zepbound status | Detail |
|---|---|---|
| Aetna | Limited coverage | CVS Caremark, the pharmacy benefit manager in Aetna's parent company CVS Health, removed Zepbound from its formulary on July 1, 2025 and lists Wegovy as the covered alternative. If your Aetna plan uses that formulary, Zepbound needs a formulary exception. Aetna's Zepbound policy (6192-C) sets the clinical bar at BMI 30, or 27 with a weight-related condition, plus 6 months in a weight management program. |
| Blue Cross Blue Shield | Varies by plan | Zepbound coverage depends on your Blue plan. Blue Cross Blue Shield of Massachusetts and Blue Cross Blue Shield of Michigan both ended weight-loss GLP-1 coverage for many members. The federal employee plan, FEP Blue, covers Zepbound with prior approval under policy 5.99.031, which requires trying two oral weight-loss drugs first. |
| UnitedHealthcare | Covered (prior auth required) | UnitedHealthcare covers Zepbound for weight loss only on plans whose sponsor elected weight-loss medication coverage. The first approval lasts 6 months, one month longer than Wegovy's, and renewal requires at least 5% weight loss from baseline. |
| Cigna | Covered (prior auth required) | Cigna applies the same BMI-tiered structure to Zepbound as to Wegovy: at least 3 months of behavior change and diet, an 8-month first approval, and at least 5% weight loss for renewal. For sleep apnea, renewal after a year requires at least 10% weight loss. |
| Humana | Limited coverage | Humana Medicare drug plans follow the Part D rule: Zepbound is not covered for weight loss alone but can be covered for moderate to severe sleep apnea. The Medicare GLP-1 Bridge covers only the Zepbound KwikPen, for $50 a month, from July 1, 2026. |
| Kaiser Permanente | Limited coverage | In Kaiser Permanente Northwest, Zepbound is non-formulary. On top of the Wegovy requirements, it needs a failed trial of semaglutide (Ozempic or Wegovy) of at least 6 months and a bariatric medicine chart review. In California, GLP-1s have not been covered for weight loss alone since January 2025. |
| Anthem | Varies by plan | Whether an Anthem commercial plan covers Zepbound for weight loss depends on the plan document, and we have not found public Anthem commercial criteria for it. Anthem's California Medi-Cal plan stopped covering Zepbound for weight loss on January 1, 2026, and still considers it for sleep apnea. |
| Medicare | Limited coverage | Part D covers Zepbound for moderate to severe sleep apnea but not for weight loss alone. The Medicare GLP-1 Bridge covers only the Zepbound KwikPen for weight loss, at $50 a month from July 1, 2026 through December 31, 2027; single-dose pens and vials are not covered. |
| Medicaid | Varies by plan | Zepbound follows each state's rules for weight-loss drugs. California Medi-Cal removed Zepbound from its drug list for weight loss on January 1, 2026, and MassHealth ended weight-loss coverage on July 3, 2026. Both still consider Zepbound for sleep apnea. |
| TRICARE | Covered (prior auth required) | TRICARE covers Zepbound for weight loss on Prime, Select and the premium-based plans under the same prior authorization form as Wegovy, but only for adults: the form does not approve Zepbound under age 18. TRICARE For Life and direct-care-only beneficiaries have had no weight-loss drug coverage since August 31, 2025. |
| GEHA | Limited coverage | For the 2026 plan year, Zepbound is non-formulary on every GEHA plan and is covered only with an approved formulary exception through CVS Caremark. Your provider could start the exception process before the January 1, 2026 change. |
| Veterans Affairs (VA) | Covered (prior auth required) | The VA's April 2026 criteria for Zepbound in weight management match its Wegovy criteria: documented lifestyle intervention such as MOVE! within the past year, and a BMI of 27 or more with at least one weight-related condition. |
Telehealth and prescribing in New York
A telehealth clinician must be licensed in New York to prescribe Zepbound to you while you are in New York.
Platforms differ in which drugs they prescribe, insurance handling, and clinical model. See our platform comparisons.
Compounded tirzepatide
On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.
Zepbound in New York: common questions
Is Zepbound legal in New York?+
Yes. Zepbound (tirzepatide) is FDA-approved and legal in all 50 US states including New York. State-level differences appear in Medicaid coverage and clinician licensing, not in the legality of the medication itself.
Can I get Zepbound via telehealth in New York?+
Yes, from a clinician licensed in New York. A telehealth clinician must be licensed in New York to prescribe Zepbound to you while you are in New York.
Does New York Medicaid cover Zepbound?+
Not covered for weight loss. NY Medicaid (NYRx) excludes drugs used for weight loss under 18 NYCRR §505.3(g)(3). GLP-1s are covered only for Medicaid-covered indications such as type 2 diabetes.
What's the cheapest way to get Zepbound in New York?+
The main paths are insurance with prior authorization if your plan covers it, manufacturer cash-pay programs, or telehealth programs that include the medication. NovoCare Pharmacy sells Wegovy pens to cash-pay patients for $349 a month ($199 a month for the first two months for new patients through December 31, 2026). LillyDirect sells Zepbound vials for $299 (2.5 mg), $399 (5 mg), and $449 (7.5 to 15 mg) a month when refilled on time.
Is compounded Zepbound still available in New York?+
Compounding rules are federal, not set by New York. On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.